Works matching IS 16639812 AND DT 2023 AND VI 14

Results: 830
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

    Published in:
    Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1154377
    By:
    • Iurlo, A.;
    • Cattaneo, D.;
    • Consonni, D.;
    • Castagnetti, F.;
    • Miggiano, M. C.;
    • Binotto, G.;
    • Bonifacio, M.;
    • Rege-Cambrin, G.;
    • Tiribelli, M.;
    • Lunghi, F.;
    • Gozzini, A.;
    • Pregno, P.;
    • Abruzzese, E.;
    • Capodanno, I.;
    • Bucelli, C.;
    • Pizzuti, M.;
    • Artuso, S.;
    • Iezza, M.;
    • Scalzulli, E.;
    • La Barba, G.
    Publication type:
    Article
    26
    27
    28
    29
    30

    Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management —Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine.

    Published in:
    Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1121950
    By:
    • Koklesova, Lenka;
    • Jakubikova, Jana;
    • Cholujova, Dana;
    • Samec, Marek;
    • Mazurakova, Alena;
    • Šudomová, Miroslava;
    • Pec, Martin;
    • Hassan, Sherif T. S.;
    • Biringer, Kamil;
    • Büsselberg, Dietrich;
    • Hurtova, Tatiana;
    • Golubnitschaja, Olga;
    • Kubatka, Peter
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50